Today: 19 July 2026
Trade Desk stock ends the week flat near $37 as CPI and earnings season set the next test
12 January 2026
1 min read

Trade Desk stock ends the week flat near $37 as CPI and earnings season set the next test

New York, Jan 11, 2026, 17:45 EST — Market closed

  • Shares of The Trade Desk ended Friday at $37.29, having fluctuated between $36.63 and $37.65 during the session
  • Tuesday’s U.S. inflation figures are set to move rate wagers and growth stocks.
  • Investors are also watching early earnings-season cues on consumer and ad spending as they await Trade Desk’s results

The Trade Desk, Inc. (TTD.O) closed Friday at $37.29, barely moving as investors brace for a week likely shaped more by inflation numbers than corporate news. Shares fluctuated from $36.63 to $37.65, with roughly 10.2 million shares traded.

U.S. markets are closed until Sunday, leaving Trade Desk’s direction largely in the hands of rate forecasts and risk sentiment once trading kicks back in. Historically, a sharp CPI surprise—up or down—has shaken up higher-growth stocks, the types that investors value based on long-term cash flows.

Trade Desk operates a self-service platform enabling advertisers and agencies to purchase digital ad space across channels like video and connected TV. Simply put, it works on the buy side of automated ad buying and earns fees based on client spending.

Wall Street finished Friday at new highs despite a softer-than-forecast U.S. jobs report, which failed to dent optimism around rate cuts this year. The S&P 500 gained 0.65%, while the Nasdaq climbed 0.82%, Reuters reported.

Coming Tuesday at 8:30 a.m. ET is the Labor Department’s consumer price index for December, one of the final major reports ahead of the Federal Reserve’s policy meeting later in January. The Fed’s two-day session is scheduled for Jan. 27-28.

Elias Haddad of Brown Brothers Harriman projects headline inflation at 2.7% year-on-year, with core inflation also expected to edge up to 2.7%. He cautions that the December CPI data should be viewed carefully, citing distortions from absent October price quotes and delayed November data collection.

Earnings season is beginning to fill the tape. Reuters, in a note looking ahead to the week, quoted investors suggesting the market has held steady but might be undervaluing near-term volatility. State Street’s Michael Arone weighed in, saying, “On balance for this year, the foundation for the market is solid.” Reuters

For Trade Desk, that balance is crucial since ad spending can pull back sharply if firms grow cautious. Its stock also tends to move alongside other rate-sensitive growth plays when yields fluctuate. A weaker CPI reading could relieve some valuation pressure; a hotter one might trigger a swift reversal.

The road ahead isn’t smooth. Should inflation spike beyond forecasts or earnings guidance signal weaker consumer demand, investors could quickly doubt the staying power of ad spending. Programmatic ad platforms might then see their valuations fall, even without any new company-specific news.

Tuesday’s CPI release at 8:30 a.m. ET kicks things off. Afterward, eyes turn to The Trade Desk, which has yet to confirm its next earnings date; Nasdaq lists Feb. 11 as the expected report.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • Neurocrine Biosciences (NBIX) Stock Fair Value and Performance in Focus
    July 19, 2026, 3:59 PM EDT. Neurocrine Biosciences (NBIX) is viewed as near fairly valued, with shares trading at a P/E ratio of 25.7x versus a fair value estimate of 26.0x. The stock has increased 73.4% over five years and posted a 29.4% gain in the past year, though this trails some competitors. Valuation signals are mixed, with about half indicating the stock could be expensive. Investors are assessing the resilience of cash flows from current therapies alongside operational risks. Growth prospects are supported by a broad pipeline, including late-stage assets and early commercial progress, yet policy changes and concentration risks are present. The overall assessment shows a valuation that reflects tempered expectations for Neurocrine's earnings potential and profitability.
BigBear.ai stock (BBAI) eyes Monday open after Kraft Group, Patriots tie-up; share vote looms
Previous Story

BigBear.ai stock (BBAI) eyes Monday open after Kraft Group, Patriots tie-up; share vote looms

GE Vernova stock pops after $1,087 price-target hike — and Wall Street’s already eyeing Jan. 28
Next Story

GE Vernova stock pops after $1,087 price-target hike — and Wall Street’s already eyeing Jan. 28

Go toTop